Abstract

The multidrug resistance protein 4 (MRP4) is a member of the ABCC subfamily of the adenosine triphosphate-binding cassette transporters that remove cyclic nucleotides from platelets and uptake ADP into dense granule in platelets. However, whether MRP4 directly involves platelet activation remains unclear. Thus, the aim of our study was to determine the detailed mechanisms underlying the regulation of MRP4 in platelet activation. Our results revealed that the MRP4 inhibitor MK571 inhibited collagen-induced platelet aggregation which was partially reversed by the PKA inhibitor H89, but not by the adenylyl cyclase (AC) inhibitor SQ22536 and the guanylyl cyclase (GC) inhibitor ODQ, suggesting that MK571 can prevent collagen-induced aggregation via a route independent of cyclic nucleotide production. In the present study, we found that MK571 inhibited collagen-induced ATP release and calcium mobilization. The phosphorylation of protein kinase C, JNK, and Akt was also inhibited by MK571, and electron spin resonance experiment showed that MK571 significantly reduced hydroxyl radical formation. Moreover, MK571 delayed platelet plug formation in vitro by a PFA-100 device, and delayed thrombus formation in mesenteric venules of mice irradiated by fluorescein sodium. However, previous studies have reported that MK571 also blocks MRP1 and leukotriene D4 (LTD 4) receptor. Therefore, whether MK571 inhibits platelet activation through MRP1 or LTD4 receptor needs to be considered and further defined. In conclusion, in addition to blocking the transport of cyclic nucleotides, MRP4 inhibition may prevent thrombus formation in vitro and in vivo. Our findings also support the idea that MRP4 may represent a potential target for the development of novel therapeutic interventions for the treatment of thromboembolic disorders.

Original languageEnglish
Pages (from-to)159-167
Number of pages9
JournalEuropean Journal of Pharmacology
Volume737
DOIs
Publication statusPublished - Aug 15 2014

Fingerprint

P-Glycoproteins
Thrombosis
Cyclic Nucleotides
Platelet Activation
Collagen
Blood Platelets
Adenosine Triphosphate
Venules
Guanylate Cyclase
Electron Spin Resonance Spectroscopy
Fluorescein
Platelet Aggregation
Hydroxyl Radical
Adenosine Diphosphate
Protein Kinase C
In Vitro Techniques
Phosphorylation
Calcium
Equipment and Supplies

Keywords

  • Cyclic nucleotide
  • MRP4
  • Platelet activation
  • Thrombus formation

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo. / Lien, Li Ming; Chen, Zhih Cherng; Chung, Chi Li; Yen, Ting Lin; Chiu, Hou Chang; Chou, Duen Suey; Huang, Shih Yi; Sheu, Joen Rong; Lu, Wan-Jung; Lin, Kuan Hung.

In: European Journal of Pharmacology, Vol. 737, 15.08.2014, p. 159-167.

Research output: Contribution to journalArticle

@article{d66b1c9798b24122a9ee5b3da1fca8e4,
title = "Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo",
abstract = "The multidrug resistance protein 4 (MRP4) is a member of the ABCC subfamily of the adenosine triphosphate-binding cassette transporters that remove cyclic nucleotides from platelets and uptake ADP into dense granule in platelets. However, whether MRP4 directly involves platelet activation remains unclear. Thus, the aim of our study was to determine the detailed mechanisms underlying the regulation of MRP4 in platelet activation. Our results revealed that the MRP4 inhibitor MK571 inhibited collagen-induced platelet aggregation which was partially reversed by the PKA inhibitor H89, but not by the adenylyl cyclase (AC) inhibitor SQ22536 and the guanylyl cyclase (GC) inhibitor ODQ, suggesting that MK571 can prevent collagen-induced aggregation via a route independent of cyclic nucleotide production. In the present study, we found that MK571 inhibited collagen-induced ATP release and calcium mobilization. The phosphorylation of protein kinase C, JNK, and Akt was also inhibited by MK571, and electron spin resonance experiment showed that MK571 significantly reduced hydroxyl radical formation. Moreover, MK571 delayed platelet plug formation in vitro by a PFA-100 device, and delayed thrombus formation in mesenteric venules of mice irradiated by fluorescein sodium. However, previous studies have reported that MK571 also blocks MRP1 and leukotriene D4 (LTD 4) receptor. Therefore, whether MK571 inhibits platelet activation through MRP1 or LTD4 receptor needs to be considered and further defined. In conclusion, in addition to blocking the transport of cyclic nucleotides, MRP4 inhibition may prevent thrombus formation in vitro and in vivo. Our findings also support the idea that MRP4 may represent a potential target for the development of novel therapeutic interventions for the treatment of thromboembolic disorders.",
keywords = "Cyclic nucleotide, MRP4, Platelet activation, Thrombus formation",
author = "Lien, {Li Ming} and Chen, {Zhih Cherng} and Chung, {Chi Li} and Yen, {Ting Lin} and Chiu, {Hou Chang} and Chou, {Duen Suey} and Huang, {Shih Yi} and Sheu, {Joen Rong} and Wan-Jung Lu and Lin, {Kuan Hung}",
year = "2014",
month = "8",
day = "15",
doi = "10.1016/j.ejphar.2014.05.001",
language = "English",
volume = "737",
pages = "159--167",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo

AU - Lien, Li Ming

AU - Chen, Zhih Cherng

AU - Chung, Chi Li

AU - Yen, Ting Lin

AU - Chiu, Hou Chang

AU - Chou, Duen Suey

AU - Huang, Shih Yi

AU - Sheu, Joen Rong

AU - Lu, Wan-Jung

AU - Lin, Kuan Hung

PY - 2014/8/15

Y1 - 2014/8/15

N2 - The multidrug resistance protein 4 (MRP4) is a member of the ABCC subfamily of the adenosine triphosphate-binding cassette transporters that remove cyclic nucleotides from platelets and uptake ADP into dense granule in platelets. However, whether MRP4 directly involves platelet activation remains unclear. Thus, the aim of our study was to determine the detailed mechanisms underlying the regulation of MRP4 in platelet activation. Our results revealed that the MRP4 inhibitor MK571 inhibited collagen-induced platelet aggregation which was partially reversed by the PKA inhibitor H89, but not by the adenylyl cyclase (AC) inhibitor SQ22536 and the guanylyl cyclase (GC) inhibitor ODQ, suggesting that MK571 can prevent collagen-induced aggregation via a route independent of cyclic nucleotide production. In the present study, we found that MK571 inhibited collagen-induced ATP release and calcium mobilization. The phosphorylation of protein kinase C, JNK, and Akt was also inhibited by MK571, and electron spin resonance experiment showed that MK571 significantly reduced hydroxyl radical formation. Moreover, MK571 delayed platelet plug formation in vitro by a PFA-100 device, and delayed thrombus formation in mesenteric venules of mice irradiated by fluorescein sodium. However, previous studies have reported that MK571 also blocks MRP1 and leukotriene D4 (LTD 4) receptor. Therefore, whether MK571 inhibits platelet activation through MRP1 or LTD4 receptor needs to be considered and further defined. In conclusion, in addition to blocking the transport of cyclic nucleotides, MRP4 inhibition may prevent thrombus formation in vitro and in vivo. Our findings also support the idea that MRP4 may represent a potential target for the development of novel therapeutic interventions for the treatment of thromboembolic disorders.

AB - The multidrug resistance protein 4 (MRP4) is a member of the ABCC subfamily of the adenosine triphosphate-binding cassette transporters that remove cyclic nucleotides from platelets and uptake ADP into dense granule in platelets. However, whether MRP4 directly involves platelet activation remains unclear. Thus, the aim of our study was to determine the detailed mechanisms underlying the regulation of MRP4 in platelet activation. Our results revealed that the MRP4 inhibitor MK571 inhibited collagen-induced platelet aggregation which was partially reversed by the PKA inhibitor H89, but not by the adenylyl cyclase (AC) inhibitor SQ22536 and the guanylyl cyclase (GC) inhibitor ODQ, suggesting that MK571 can prevent collagen-induced aggregation via a route independent of cyclic nucleotide production. In the present study, we found that MK571 inhibited collagen-induced ATP release and calcium mobilization. The phosphorylation of protein kinase C, JNK, and Akt was also inhibited by MK571, and electron spin resonance experiment showed that MK571 significantly reduced hydroxyl radical formation. Moreover, MK571 delayed platelet plug formation in vitro by a PFA-100 device, and delayed thrombus formation in mesenteric venules of mice irradiated by fluorescein sodium. However, previous studies have reported that MK571 also blocks MRP1 and leukotriene D4 (LTD 4) receptor. Therefore, whether MK571 inhibits platelet activation through MRP1 or LTD4 receptor needs to be considered and further defined. In conclusion, in addition to blocking the transport of cyclic nucleotides, MRP4 inhibition may prevent thrombus formation in vitro and in vivo. Our findings also support the idea that MRP4 may represent a potential target for the development of novel therapeutic interventions for the treatment of thromboembolic disorders.

KW - Cyclic nucleotide

KW - MRP4

KW - Platelet activation

KW - Thrombus formation

UR - http://www.scopus.com/inward/record.url?scp=84901873303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901873303&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2014.05.001

DO - 10.1016/j.ejphar.2014.05.001

M3 - Article

C2 - 24836986

AN - SCOPUS:84901873303

VL - 737

SP - 159

EP - 167

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -